Related Experiment Video
Updated: Dec 29, 2025
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Ventilator-associated pneumonia: new principles guiding empiric antibiotic therapy
Cristina Dominedò1, Adrian Ceccato2,3, Antoni Torres2
1Department of Anesthesiology and Intensive Care Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy.
Purpose Of Review:
Ventilator-associated pneumonia (VAP) is a serious event in critically ill patients. We aim to review the most recent evidences about VAP, including its cause, the main differences between the American and European guidelines in the definition of risk factors for multidrug-resistant pathogens, the main principles guiding empirical antibiotic treatment, and the potential role of molecular diagnostic tests.
Recent Findings:
The 2016 ATS/IDSA and the 2017 ERS/ESICM/ESCMID/ALAT guidelines provide different approaches for the management of VAP. Both guidelines highlight the need to use local epidemiological data for antibiotic choice; however, they identify different risk factors that can assist with decision making when local data are not available. Nevertheless, validation studies of the American guidelines suggest that empiric antibiotic therapy based on risk factors may lead to an overuse of broad-spectrum antibiotics. Rapid diagnostic tests may allow a faster identification of VAP cause, resulting in more adequate antimicrobial therapy and reduced exposition to broad-spectrum antibiotics.
Summary:
Clinical studies should be conducted to evaluate the benefits of implementing guidelines and new approaches such as combinations of clinical data with rapid diagnostic tests; meantime adaptations of guidelines to local settings should be carried out by a local multidisciplinary expert team.
Insights
Ventilator-associated pneumonia (VAP) management differs between guidelines. Rapid diagnostic tests may improve antibiotic therapy and reduce broad-spectrum antibiotic use in critically ill patients.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Pulmonology
Background:
- Ventilator-associated pneumonia (VAP) is a significant complication in intensive care units.
- Current guidelines offer differing strategies for VAP management and risk stratification for multidrug-resistant pathogens.
Purpose of the Study:
- To review current evidence on VAP, focusing on etiology, guideline discrepancies, empirical antibiotic treatment, and molecular diagnostics.
- To compare American and European guidelines regarding risk factors for multidrug-resistant pathogens in VAP.
Main Methods:
- Review of recent scientific literature and clinical guidelines.
- Comparative analysis of the 2016 ATS/IDSA and 2017 ERS/ESICM/ESCMID/ALAT guidelines for VAP management.
Main Results:
- Guidelines differ in identifying risk factors for multidrug-resistant pathogens, potentially leading to overuse of broad-spectrum antibiotics.
- Rapid diagnostic tests show promise for faster VAP pathogen identification, enabling more targeted antimicrobial therapy.
- Local epidemiological data are crucial for antibiotic selection, but risk factor-based decisions may require re-evaluation.
Conclusions:
- Further clinical studies are needed to assess the impact of guideline implementation and novel diagnostic approaches.
- Integrating rapid diagnostic tests with clinical data may optimize VAP treatment and reduce antibiotic exposure.
- Adaptation of VAP guidelines to local contexts by multidisciplinary teams is recommended.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Pneumonia III: Complications and Assessment
01:29Pneumonia II: Pathophysiology
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...